Nothing Special   »   [go: up one dir, main page]

MX2021007070A - Mutantes de proteina f de rsv. - Google Patents

Mutantes de proteina f de rsv.

Info

Publication number
MX2021007070A
MX2021007070A MX2021007070A MX2021007070A MX2021007070A MX 2021007070 A MX2021007070 A MX 2021007070A MX 2021007070 A MX2021007070 A MX 2021007070A MX 2021007070 A MX2021007070 A MX 2021007070A MX 2021007070 A MX2021007070 A MX 2021007070A
Authority
MX
Mexico
Prior art keywords
rsv
protein mutants
protein
mutants
compositions
Prior art date
Application number
MX2021007070A
Other languages
English (en)
Inventor
Ping Cai
Xiayang Qiu
Philip Ralph Dormitzer
Mark Edward Ruppen
Avvari Krishna Prasad
Ye Che
Alexey Vyacheslavovich Gribenko
Luke David Handke
Xi Song
Kena Anne Swanson
Srinivas Kodali
KariAnn Sweeney Efferen
Kristin Rachael Tompkins
Lorna del Pilar Nunez
Xin Xu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2021007070A publication Critical patent/MX2021007070A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se relaciona con mutantes, ácidos nucleicos o vectores de proteína F de RSV, que codifican un mutante de proteína F de RSV, composiciones o ácidos nucleicos que comprenden un mutante de proteína F de RSV, y usos de los mutantes, ácidos nucleicos o vectores de proteína F de RSV y composiciones.
MX2021007070A 2015-12-23 2018-06-20 Mutantes de proteina f de rsv. MX2021007070A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387270P 2015-12-23 2015-12-23
US201662421184P 2016-11-11 2016-11-11

Publications (1)

Publication Number Publication Date
MX2021007070A true MX2021007070A (es) 2021-08-11

Family

ID=57590746

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018007622A MX2018007622A (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv.
MX2021007070A MX2021007070A (es) 2015-12-23 2018-06-20 Mutantes de proteina f de rsv.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018007622A MX2018007622A (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv.

Country Status (19)

Country Link
US (5) US9950058B2 (es)
EP (1) EP3393512A1 (es)
JP (4) JP6817307B2 (es)
KR (3) KR102136678B1 (es)
CN (1) CN108738312A (es)
AU (4) AU2016379097C1 (es)
BR (1) BR112018010805A2 (es)
CA (2) CA2952131C (es)
CO (1) CO2018006301A2 (es)
IL (2) IL260203B2 (es)
MX (2) MX2018007622A (es)
MY (1) MY205060A (es)
PE (3) PE20181354A1 (es)
PH (1) PH12018501355A1 (es)
RU (1) RU2723039C2 (es)
SA (2) SA522433260B1 (es)
SG (2) SG10202001389PA (es)
TW (4) TWI838685B (es)
WO (1) WO2017109629A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3024483B1 (en) 2013-07-25 2020-01-15 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CN110603262A (zh) 2017-04-04 2019-12-20 华盛顿大学 显示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途
WO2019032480A1 (en) 2017-08-07 2019-02-14 Avatar Medical, Llc PROTEINS F PRE-FUSION OF RSV STABILIZED IN TERMS OF CONFORMATION
CN111655715A (zh) 2018-01-29 2020-09-11 默沙东公司 稳定化的rsv f蛋白及其用途
EP3758747A1 (en) 2018-02-28 2021-01-06 University of Washington Self-asssembling nanostructure vaccines
CN112601545A (zh) 2018-08-07 2021-04-02 葛兰素史密丝克莱恩生物有限公司 工艺和疫苗
BR112021008975A2 (pt) * 2018-11-13 2021-08-17 Janssen Vaccines & Prevention B.V. proteínas f do rsv pré-fusão estabilizadas
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN110054668B (zh) * 2019-04-25 2021-09-10 北京交通大学 一种呼吸道合胞病毒融合前f蛋白及其应用
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
EP4025587A1 (en) 2019-09-04 2022-07-13 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US20230086093A1 (en) * 2019-12-23 2023-03-23 Mitsubishi Tanabe Pharma Corporation Mutant rsv f protein and use thereof
US11857622B2 (en) * 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
CN112899214B (zh) * 2020-07-07 2023-08-04 湖南师范大学 废弃鱼鳞在制备各向异性基底中的应用
JP2022023813A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
JP2022023814A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN114685676B (zh) * 2020-12-28 2024-02-13 兰州生物制品研究所有限责任公司 一种重组蛋白及其表达方法、纯化方法及用途
EP4294436A1 (en) * 2021-02-19 2023-12-27 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb fantigens
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN117715923A (zh) * 2022-04-29 2024-03-15 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
WO2024041772A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
CN116003536A (zh) * 2022-09-23 2023-04-25 暨南大学 呼吸道合胞病毒融合前f蛋白突变体及其应用
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
TW202424187A (zh) 2022-10-27 2024-06-16 美商輝瑞大藥廠 Rna分子
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
CN117986382A (zh) * 2022-11-04 2024-05-07 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
WO2024194153A1 (en) * 2023-03-17 2024-09-26 Glaxosmithkline Biologicals Sa Rsv-f-encoding nucleic acids
CN118078975A (zh) * 2023-03-17 2024-05-28 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗
WO2024199114A1 (en) * 2023-03-24 2024-10-03 Starna Therapeutics Nucleic acids encoding therapeutic polypeptides and lipid nanoparticle composition comprising the nucleic acids
CN118725052A (zh) * 2023-03-31 2024-10-01 清华大学 具有稳定融合前构象的呼吸道合胞病毒f蛋白
CN117487823B (zh) * 2023-09-28 2024-10-29 怡道生物科技(苏州)有限公司 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用
CN117304280B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304279B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304278B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN117645655B (zh) * 2024-01-26 2024-05-24 普大生物科技(泰州)有限公司 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法
CN117777251B (zh) * 2024-02-27 2024-06-04 普大生物科技(泰州)有限公司 一种rsv纳米颗粒疫苗及其制备方法
CN118064456B (zh) * 2024-03-01 2024-10-29 嘉译生物医药(杭州)有限公司 一种针对人合胞病毒的新型的RSV B mRNA疫苗

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
EP2181121A4 (en) 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2164860A2 (en) 2007-06-06 2010-03-24 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
CN101952321B (zh) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 重组rsv抗原
CN102131830A (zh) 2008-07-18 2011-07-20 魁北克益得生物医学公司 嵌合呼吸道合胞病毒多肽抗原
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
CN106146671B (zh) 2008-12-09 2020-03-31 诺瓦瓦克斯股份有限公司 修饰的rsv f蛋白及其使用方法
CA2766205A1 (en) * 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
PE20121541A1 (es) * 2009-06-24 2012-12-21 Glaxosmithkline Biolog Sa Antigenos de virus de sincicio respiratorio recombinantes
PL3178490T3 (pl) * 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
EP2486053B1 (en) 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
RS56748B1 (sr) * 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
ES2395677B1 (es) 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
MX2014003777A (es) 2011-09-30 2015-05-15 Novavax Inc Vacuna de nanoparticulas de proteinas f del rsv recombinantes para el virus respiratorio sincitial.
AU2013237424B2 (en) 2012-03-22 2017-07-06 Janssen Vaccines & Prevention B.V. Vaccine against RSV
BR112015011389A2 (pt) 2012-11-20 2017-08-22 Glaxosmithkline Biologicals Sa Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CA2902877A1 (en) 2013-03-13 2014-10-02 Jeffrey Boyington Prefusion rsv f proteins and their use
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3024483B1 (en) * 2013-07-25 2020-01-15 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
US20150166610A1 (en) * 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US11324816B2 (en) * 2015-08-31 2022-05-10 Technovax, Inc. Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
US10496141B2 (en) 2016-03-17 2019-12-03 Qualcomm Incorporated System and method for intelligent thermal management in a system on a chip having a heterogeneous cluster architecture

Also Published As

Publication number Publication date
TWI838685B (zh) 2024-04-11
IL260203B1 (en) 2024-05-01
RU2020115606A (ru) 2020-06-29
IL260203A (en) 2018-07-31
AU2021202522B2 (en) 2023-05-11
BR112018010805A2 (pt) 2018-11-27
TW201920238A (zh) 2019-06-01
AU2019210579B2 (en) 2021-01-28
US20230218738A1 (en) 2023-07-13
KR20230035429A (ko) 2023-03-13
WO2017109629A1 (en) 2017-06-29
JP7193522B2 (ja) 2022-12-20
CA2952131C (en) 2023-12-05
TW201726709A (zh) 2017-08-01
TWI656130B (zh) 2019-04-11
AU2016379097C1 (en) 2021-04-08
US20180177864A1 (en) 2018-06-28
RU2020115606A3 (es) 2020-11-23
IL311990A (en) 2024-06-01
KR102136678B1 (ko) 2020-07-22
CN108738312A (zh) 2018-11-02
SG10202001389PA (en) 2020-04-29
PE20232039A1 (es) 2023-12-21
MX2018007622A (es) 2018-11-14
PE20181354A1 (es) 2018-08-22
TWI707866B (zh) 2020-10-21
AU2021202522A1 (en) 2021-05-27
SA518391839B1 (ar) 2023-10-22
US10238732B2 (en) 2019-03-26
KR102505354B1 (ko) 2023-03-02
JP2019511998A (ja) 2019-05-09
TW202216738A (zh) 2022-05-01
JP6817307B2 (ja) 2021-01-20
AU2016379097B2 (en) 2019-08-22
PE20240817A1 (es) 2024-04-18
AU2021202522C1 (en) 2023-11-23
CA3217696A1 (en) 2017-06-23
KR20200090932A (ko) 2020-07-29
US10821171B2 (en) 2020-11-03
JP7212198B2 (ja) 2023-01-24
PH12018501355A1 (en) 2019-02-18
AU2023214269A1 (en) 2023-10-12
RU2723039C2 (ru) 2020-06-08
RU2018122823A3 (es) 2020-01-23
EP3393512A1 (en) 2018-10-31
TW202124414A (zh) 2021-07-01
AU2016379097A1 (en) 2018-06-07
US20190125861A1 (en) 2019-05-02
CA2952131A1 (en) 2017-06-23
AU2019210579A1 (en) 2019-08-22
TWI756828B (zh) 2022-03-01
US20210023200A1 (en) 2021-01-28
IL260203B2 (en) 2024-09-01
JP2023015335A (ja) 2023-01-31
US9950058B2 (en) 2018-04-24
CO2018006301A2 (es) 2018-07-10
SA522433260B1 (ar) 2024-06-24
JP2021061845A (ja) 2021-04-22
JP2022185022A (ja) 2022-12-13
MY205060A (en) 2024-09-30
SG11201804148TA (en) 2018-07-30
US20170182151A1 (en) 2017-06-29
KR20180081614A (ko) 2018-07-16
RU2018122823A (ru) 2020-01-23

Similar Documents

Publication Publication Date Title
PH12018501355A1 (en) Rsv f protein mutants
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
EP3741848A3 (en) Protease variants and polynucleotides encoding same
WO2016066756A3 (en) Protease variants and polynucleotides encoding same
WO2016066757A3 (en) Protease variants and polynucleotides encoding same
MX2023010757A (es) Variantes de proteasa y sus usos.
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
EP3741849A3 (en) Protease variants and polynucleotides encoding same
EP3708660A3 (en) Polypeptides
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
MX2017007731A (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2019000140A (es) Variantes de xilanasa y polinucleotidos que las codifican.
WO2015014790A3 (en) Protease variants and polynucleotides encoding same
WO2015048334A3 (en) Edible species nutritive polypeptides and methods of production and use thereof
WO2016062875A3 (en) Glucoamylase variants and polynucleotides encoding same
MX2018008051A (es) Variantes de beta-glucanasa y polinucleotidos que las codifican.
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2016140859A3 (en) Protoxin-ii variants and methods of use
WO2017112847A8 (en) Improved protein expression strains
MX2023003394A (es) Variantes de proteasa y sus usos.
MX2017007105A (es) Variantes de lipasa y polinucleotidos que las codifican.
MX2017008908A (es) Proceso para la hidrólisis de queratina empleando proteasas.